Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02104752
Recruitment Status : Completed
First Posted : April 4, 2014
Last Update Posted : October 23, 2017
Stanley Medical Research Institute
Theravalues, Inc.
University of California, Los Angeles
Information provided by (Responsible Party):
Michael C. Davis, M.D., Ph.D., VA Greater Los Angeles Healthcare System

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : May 2016
  Actual Study Completion Date : October 2017

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 October 30, 2017
November 30, 2017
2 May 8, 2018
June 7, 2018
Publications automatically indexed to this study by Identifier (NCT Number):